SFI
ODT

Susquehanna Fundamental Investments’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,280
Closed -$64K – 1970
2021
Q2 		$64K Buy
+18,280
New +$62.8K ﹤0.01% 1605

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's ODT Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2021, closing a stake of 18,280 shares — an estimated $64K sold.

Susquehanna Fundamental Investments first reported a position in ODT in Q2 2021 and held it in 1 quarter. The position peaked at $64K in Q2 2021. 58 funds tracked by Wall St. Rank hold ODT as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 18,280 Odonate Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $64K.
  • Susquehanna Fundamental Investments first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Odonate Therapeutics, Inc. Common Stock position peaked at $64K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.